Comparison of platelet concentrates obtained with two different plateletpheresis programs of MCS®+

Infusionstherapie und Transfusionsmedizin

Volumn 29, Issue 1, 2002, Pages 12-16

  Stiegler, Grabiele ^a   Leitner, G ^a   Panzer, S ^a   Hocker P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adverse events of citrate; Collection efficiency; Plateletpheresis; White blood cells

Indexed keywords

CITRIC ACID; THROMBOCYTE CONCENTRATE;

ACCURACY; ADULT; ARTICLE; BLOOD DONOR; CELL COUNT; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LEUKOCYTE; MALE; NORMAL HUMAN; PH; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; SAFETY; THROMBOCYTOPHERESIS;

EID: 0036187705     PISSN: 14245485     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
2. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
3. White cell reduction in platelet concentrates and packed red cells by filtration: A multicenter clinical trial
4. Prevention of transfusion-aquired cytomegalovirus infection in infants by blood filtration to remove leukocytes
5. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
6. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood
7. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplants recipients by the removal of white cells from blood components with high-affinity filters
8. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
9. Leukocyte-reduction to prevent transfusion-transmitted cytomegalovirus infections
10. Biologic effects of leukocytes present in transfusion cellular blood products
11. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system
12. Plateletpheresis with a next generation blood cell separator
13. Platelet collection with the Amicus and AS.TEC 204 blood cell separators
14. Evaluation of the Amicus separator in the collection of apheresis platelets
15. White cell reduction during plateletpheresis: A comparison of three blood cell separators
16. Periodic alternating interface positioning to lower WBC contamination of apheresis platelet concentrates: A multicenter evaluation
17. Preparation of leukocyte-depleted thrombocyte concentrate: In-vitro testing of a new filter system (PL100)
18. Filtration of platelet concentrates
19. The mechanism of white cell reduction by synthetic fiber cell filters
20. The flow rate significantly influences the leukocyte depletion rate during prestorage in-line filtration of platelet concentrates
21. Improved removal of white cells with minimal platelet loss by filtration of apheresis platelets during collection
22. Frequency of immediate adverse effects associated with apheresis donation
23. Plateletpheresis efficiency: A comparison of the Spectra LRS and AMICUS separators
24. Studies on the improvement of leucodepletion performance of the Haemonetics MCS+ for production of leucode-pleted platelet concentrates
25. Leukodepletion of platelet concentrates and plasma collected with Haemonetics™ MCS+ apheresis system. Experience of AFS-Alsace
26. Comparison of a new WBC-reduction system and the standard plateletpheresis protocol in the same donor
27. Platelet transfusion: A dose-response study
28. Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program
29. Comprehensive analysis of citrate effects during plateletpheresis in normal donors